Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHEST-2: Riociguat Long-term Extension in CTEPH
NCT00910429Phase 3Completed
- Sponsor
- Bayer
- Start
- Jul 2009
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 26
01
Overview
A Phase 3 trial of riociguat in chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by Bayer. Started Jul 2009; status: completed.
02
Drugs
riociguat
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NCT00910429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00910429.